

www.azte.com



Inventors

Sidney Hecht

Director, Center of BioEnergetics The Biodesign Institute Arizona State University

Jeffrey Armstrong

Assistant Research Professor The Biodesign Institute Arizona State University

Omar Khdour

Postdoctoral Fellow The Biodesign Institute Arizona State University

Jun Lu

Research Scientist The Biodesign Institute Arizona State University

Pablo Arce Research Assistant The Biodesign Institute Arizona State University

Intellectual Property Status: Patent Pending

Contact

Jack Geltosky, PhD

Senior Vice President

Business Development, Life Sciences

Arizona Technology Enterprises, LLC (AzTE)

P: 480.884.1989

F: 480.884.1984

JGELTOSKY@AZTE.COM HEALTHSCIENCES@AZTE.COM

Reducing Oxidative Stress with Multifunctional Radical Quenchers

AzTE Case # M10-073

Invention Description

Mitochondria are intracellular organelles responsible for a number of metabolic transformations and regulatory functions. They produce much of the ATP employed by eukaryotic cells. They are also the major source of free radicals and reactive oxygen species that cause oxidative stress.

Mitochondrial defects are damaging, particularly to neural and muscle tissues which have high energy demands. Energetic defects have been implicated in forms of movement disorders, cardiomyopathy, myopathy, blindness, and deafness. Currently, there are no effective treatments for mitochondrial diseases.

Researchers at the Biodesign Institute of Arizona State University have developed compounds to treat diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation. The compounds discovered are multifunctional radical quenchers, which prevent ROSdependent cell death scavenging oxygen free radicals and lipid peroxidation by quenching C-centered lipid radicals.

These compounds represent a novel class of potential therapeutics for a variety of diseases associated with decreased mitochondrial function, including Friedreich's ataxia, Leber's Hereditary Optic Neuropathy, Kearns-Sayre Syndrome, Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes.

Potential Applications

- Mitochondrial diseases:
 - Friedreich's ataxia, Leber's Hereditary Optic Neuropathy, Kearns-Sayre Syndrome, Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-Like Episodes (Leigh syndrome)

Benefits and Advantages

More effective than idebenone or a-tocopherol (antioxidants)